Supplemental conventional transarterial embolization/chemoembolization therapy via extrahepatic arteries for hepatocellular carcinoma
Autor: | Jianfei Tu, Yuanqan Huang, Guomin Jiang, Zhongzhi Jia, Feng Tian, Tao Shen |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Adult
Male medicine.medical_specialty Carcinoma Hepatocellular Organoplatinum Compounds Cystic artery Gastroenterology lcsh:RC254-282 030218 nuclear medicine & medical imaging 03 medical and health sciences Extrahepatic artery 0302 clinical medicine Internal medicine medicine.artery medicine Carcinoma Humans Radiology Nuclear Medicine and imaging Chemoembolization Therapeutic Transcatheter arterial chemoembolization Survival rate Aged Epirubicin Aged 80 and over business.industry Liver Neoplasms Arteries General Medicine hepatocellular carcinoma Middle Aged Inferior phrenic arteries medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Adrenal artery Oxaliplatin Survival Rate medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Hepatocellular carcinoma Female alpha-Fetoproteins Radiology Tomography X-Ray Computed business Artery transcatheter arterial chemoembolization |
Zdroj: | Journal of Cancer Research and Therapeutics, Vol 13, Iss 4, Pp 720-724 (2017) |
ISSN: | 1998-4138 0973-1482 |
Popis: | Purpose: To assess the value of conventional transarterial embolization/chemoembolization (cTAE/TACE) therapy via extrahepatic arteries for patients with unresectable hepatocellular carcinoma (HCC). Methods: Patients with unresectable HCC who underwent cTAE/TACE therapy via extrahepatic arteries between May 2008 and July 2016 across 4 medical centers were identified. The technical success, serum alpha-fetoprotein (AFP) levels changes, tumor response, disease control rate, survival rate, and major complication were analyzed. Results: A total of 185 patients (167 male and 18 female) were included in this study. A total of 401 procedures were performed of the 185 patients, with 2.2 ± 0.4 procedures for each patient. A total of 197 extrahepatic arteries were identified, including inferior phrenic artery (n = 80), omental artery (n = 39), gastric artery (n = 22), right renal capsular artery (n = 21), adrenal artery (n = 13), cystic artery (n = 11), and right internal mammary artery (n = 11). The technical success rate was 96.8% (179/185). The serum AFP levels were significantly reduced at 1 month after treatment in 71 patients whose AFP ≥400 ng/mL preprocedure (P < 0.01). The disease control rate was 93% (172/185) at 3 months after cTAE/TACE, with partial response, stable disease, or progressive disease of 115, 57, and 13 patients, respectively. The cumulative survival rate from the time of cTAE/TACE via extrahepatic arteries was 100% at 6 months. There were no embolization-related major complications. Conclusion: cTAE/TACE therapy via the extrahepatic arteries can reduce the incidence of presence of residual HCC, and improve the therapeutic efficacy of cTAE/TACE. |
Databáze: | OpenAIRE |
Externí odkaz: |